BenevolentAI

BenevolentAI is a pioneer and leader in applying advanced AI to drug discovery and development.  In a world where drug development failure rate exceeds 90% and thousands of complex diseases lack treatment, our technology can increase the probability of success and reduce timelines.  Our proprietary Benevolent PlatformTM is one of the industry's most established and validated AI drug discovery technologies. Expertise across Target Identification, Chemistry and Drug Repurposing enables us to deliver across the entire R&D lifecycle. We unite science and technology to serve patients with complex diseases – because it matters. BenevolentAI is headquartered in London, UK.